Compare $AKTX vs $GTBP | Chartloom

Compare

$AKTX vs $GTBP

Akari Therapeutics PLC · GT Biopharma Inc

AKTX

Akari Therapeutics PLC

GTBP

GT Biopharma Inc

Compare $AKTX vs $GTBP

Comparing Akari Therapeutics PLC and GT Biopharma Inc

AKTXAkari Therapeutics PLC

GTBPGT Biopharma Inc

AKTXAkari Therapeutics PLC

Market cap

$17M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-24.4%

52W performance

-78.5%

FCF yield

-63.0%

GTBPGT Biopharma Inc

Market cap

$296M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-67.3%

52W performance

-75.3%

FCF yield

-4.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKTX

GTBP

Detailed metrics comparison

AKTX

Akari Therapeutics PLC

GTBP

GT Biopharma Inc

Market Cap

AKTX$17M

GTBP$296M

Enterprise Value

AKTX$10M

GTBP$291M

Price

AKTX$8.77

GTBP$6.68

P/E Ratio

AKTXN/A

GTBPN/A

P/S Ratio

AKTX0.00x

GTBP174.71x

EV/Sales

AKTX0.00x

GTBP95.98x

EV/EBITDA

AKTX0.00x

GTBP0.00x

P/B Ratio

AKTX0.83x

GTBP3.08x

P/FCF Ratio

AKTXN/A

GTBPN/A

EV/FCF

AKTX-0.94x

GTBP-20.19x

PEG Ratio

AKTXN/A

GTBPN/A

Forward P/E (NTM)

AKTXN/A

GTBPN/A

Forward P/S (NTM)

AKTXN/A

GTBPN/A

Revenue (TTM)

AKTX$0

GTBP$0

Revenue Growth (YoY)

AKTXN/A

GTBPN/A

Forward Rev Growth

AKTX137.9%

GTBP216.5%

Gross Margin (TTM)

AKTX0.0%

GTBP36.5%

Operating Margin (TTM)

AKTX0.0%

GTBP0.0%

EBITDA Margin (TTM)

AKTX0.0%

GTBP0.0%

Net Margin (TTM)

AKTX0.0%

GTBP0.0%

FCF Margin (TTM)

AKTXN/A

GTBPN/A

Net Income (TTM)

AKTX$-31M

GTBP$-33M

FCF (TTM)

AKTX$-11M

GTBP$-14M

EPS (TTM)

AKTX-$0.40

GTBP-$21.10

ROE (TTM)

AKTX-14745.0%

GTBP-44308.0%

ROA (TTM)

AKTX-7470.0%

GTBP-31311.0%

ROIC (TTM)

AKTX-14027.0%

GTBP-44308.0%

Cash

AKTX$8M

GTBP$5M

Debt

AKTX$693K

GTBP$0

Net Cash/Debt

AKTX$7M

GTBP$5M

Current Ratio (TTM)

AKTX0.60x

GTBP2.61x

Quick Ratio (TTM)

AKTX0.56x

GTBP2.51x

Debt/Equity (TTM)

AKTX0.04x

GTBP0.00x

Debt/Assets (TTM)

AKTX0.0%

GTBP0.0%

Interest Coverage (TTM)

AKTXN/A

GTBPN/A

Net Debt/EBITDA (TTM)

AKTX0.00x

GTBP0.00x

Beta

AKTX1.48

GTBP0.81

52W Performance

AKTX-78.5%

GTBP-75.3%

YTD Performance

AKTX-24.4%

GTBP-67.3%

% from 52W High

AKTX-79.5%

GTBP-76.8%

% from 52W Low

AKTX190.4%

GTBP36.0%

Asset Turnover (TTM)

AKTX0.00x

GTBP0.08x

FCF Yield (TTM)

AKTX-63.0%

GTBP-4.9%

Earnings Yield (TTM)

AKTX-181.3%

GTBP-11.1%

Dividend Yield (TTM)

AKTXN/A

GTBPN/A

Rule of 40

AKTX0.0

GTBP0.0

EV/GP/RG

AKTXN/A

GTBPN/A

Ticker research

View AKTX research View GTBP research

Metric	AKTX Akari Therapeutics PLC	GTBP GT Biopharma Inc
Market & Valuation
Market Cap	$17M	$296M
Enterprise Value	$10M	$291M
Price	$8.77	$6.68
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	174.71x
EV/Sales	0.00x	95.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.83x	3.08x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.94x	-20.19x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	137.9%	216.5%
Profitability
Gross Margin (TTM)	0.0%	36.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-31M	$-33M
FCF (TTM)	$-11M	$-14M
EPS (TTM)	-$0.40	-$21.10
ROE (TTM)	-14745.0%	-44308.0%
ROA (TTM)	-7470.0%	-31311.0%
ROIC (TTM)	-14027.0%	-44308.0%
Financial Health
Cash	$8M	$5M
Debt	$693K	$0
Net Cash/Debt	$7M	$5M
Current Ratio (TTM)	0.60x	2.61x
Quick Ratio (TTM)	0.56x	2.51x
Debt/Equity (TTM)	0.04x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.48	0.81
52W Performance	-78.5%	-75.3%
YTD Performance	-24.4%	-67.3%
% from 52W High	-79.5%	-76.8%
% from 52W Low	190.4%	36.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.08x
FCF Yield (TTM)	-63.0%	-4.9%
Earnings Yield (TTM)	-181.3%	-11.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AKTX research	View GTBP research

Valuation

P/S Ratio

AKTX

0.00x

GTBP

174.71x

EV/FCF

GTBP

-20.19x

AKTX

-0.94x

Growth & revenue

Forward Revenue Growth

GTBP

216.5%

AKTX

137.9%

Profitability & performance

Gross Margin

GTBP

36.5%

AKTX

0.0%

ROE

AKTX

-14745.0%

GTBP

-44308.0%

FCF Yield %

GTBP

-4.9%

AKTX

-63.0%

52-Week Performance

GTBP

-75.3%

AKTX

-78.5%

Detailed metrics comparison

AKTX

Akari Therapeutics PLC

GTBP

GT Biopharma Inc

Market Cap

AKTX$17M

GTBP$296M

Enterprise Value

AKTX$10M

GTBP$291M

Price

AKTX$8.77

GTBP$6.68

P/E Ratio

AKTXN/A

GTBPN/A

P/S Ratio

AKTX0.00x

GTBP174.71x

EV/Sales

AKTX0.00x

GTBP95.98x

EV/EBITDA

AKTX0.00x

GTBP0.00x

P/B Ratio

AKTX0.83x

GTBP3.08x

P/FCF Ratio

AKTXN/A

GTBPN/A

EV/FCF

AKTX-0.94x

GTBP-20.19x

PEG Ratio

AKTXN/A

GTBPN/A

Forward P/E (NTM)

AKTXN/A

GTBPN/A

Forward P/S (NTM)

AKTXN/A

GTBPN/A

Revenue (TTM)

AKTX$0

GTBP$0

Revenue Growth (YoY)

AKTXN/A

GTBPN/A

Forward Rev Growth

AKTX137.9%

GTBP216.5%

Gross Margin (TTM)

AKTX0.0%

GTBP36.5%

Operating Margin (TTM)

AKTX0.0%

GTBP0.0%

EBITDA Margin (TTM)

AKTX0.0%

GTBP0.0%

Net Margin (TTM)

AKTX0.0%

GTBP0.0%

FCF Margin (TTM)

AKTXN/A

GTBPN/A

Net Income (TTM)

AKTX$-31M

GTBP$-33M

FCF (TTM)

AKTX$-11M

GTBP$-14M

EPS (TTM)

AKTX-$0.40

GTBP-$21.10

ROE (TTM)

AKTX-14745.0%

GTBP-44308.0%

ROA (TTM)

AKTX-7470.0%

GTBP-31311.0%

ROIC (TTM)

AKTX-14027.0%

GTBP-44308.0%

Cash

AKTX$8M

GTBP$5M

Debt

AKTX$693K

GTBP$0

Net Cash/Debt

AKTX$7M

GTBP$5M

Current Ratio (TTM)

AKTX0.60x

GTBP2.61x

Quick Ratio (TTM)

AKTX0.56x

GTBP2.51x

Debt/Equity (TTM)

AKTX0.04x

GTBP0.00x

Debt/Assets (TTM)

AKTX0.0%

GTBP0.0%

Interest Coverage (TTM)

AKTXN/A

GTBPN/A

Net Debt/EBITDA (TTM)

AKTX0.00x

GTBP0.00x

Beta

AKTX1.48

GTBP0.81

52W Performance

AKTX-78.5%

GTBP-75.3%

YTD Performance

AKTX-24.4%

GTBP-67.3%

% from 52W High

AKTX-79.5%

GTBP-76.8%

% from 52W Low

AKTX190.4%

GTBP36.0%

Asset Turnover (TTM)

AKTX0.00x

GTBP0.08x

FCF Yield (TTM)

AKTX-63.0%

GTBP-4.9%

Earnings Yield (TTM)

AKTX-181.3%

GTBP-11.1%

Dividend Yield (TTM)

AKTXN/A

GTBPN/A

Rule of 40

AKTX0.0

GTBP0.0

EV/GP/RG

AKTXN/A

GTBPN/A

Ticker research

View AKTX research View GTBP research

Metric	AKTX Akari Therapeutics PLC	GTBP GT Biopharma Inc
Market & Valuation
Market Cap	$17M	$296M
Enterprise Value	$10M	$291M
Price	$8.77	$6.68
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	174.71x
EV/Sales	0.00x	95.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.83x	3.08x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.94x	-20.19x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	137.9%	216.5%
Profitability
Gross Margin (TTM)	0.0%	36.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-31M	$-33M
FCF (TTM)	$-11M	$-14M
EPS (TTM)	-$0.40	-$21.10
ROE (TTM)	-14745.0%	-44308.0%
ROA (TTM)	-7470.0%	-31311.0%
ROIC (TTM)	-14027.0%	-44308.0%
Financial Health
Cash	$8M	$5M
Debt	$693K	$0
Net Cash/Debt	$7M	$5M
Current Ratio (TTM)	0.60x	2.61x
Quick Ratio (TTM)	0.56x	2.51x
Debt/Equity (TTM)	0.04x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.48	0.81
52W Performance	-78.5%	-75.3%
YTD Performance	-24.4%	-67.3%
% from 52W High	-79.5%	-76.8%
% from 52W Low	190.4%	36.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.08x
FCF Yield (TTM)	-63.0%	-4.9%
Earnings Yield (TTM)	-181.3%	-11.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AKTX research	View GTBP research